Pulike Biological Engineering, Inc.

Shanghai Stock Exchange 603566.SS

Pulike Biological Engineering, Inc. EBT Margin for the year ending December 31, 2023: 15.54%

Pulike Biological Engineering, Inc. EBT Margin is 15.54% for the year ending December 31, 2023, a 3.68% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Pulike Biological Engineering, Inc. EBT Margin for the year ending December 31, 2022 was 14.98%, a -42.07% change year over year.
Pulike Biological Engineering, Inc. EBT Margin for the year ending December 31, 2021 was 25.87%, a -7.62% change year over year.
Pulike Biological Engineering, Inc. EBT Margin for the year ending December 31, 2020 was 28.00%, a 58.47% change year over year.
Pulike Biological Engineering, Inc. EBT Margin for the year ending December 31, 2019 was 17.67%, a -29.87% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

Shanghai Stock Exchange: 603566.SS

Pulike Biological Engineering, Inc.

CEO	Mr. Wei Hu
IPO Date	May 18, 2015
Location	China
Headquarters	No.15 Zhenghe Road
Employees	1,679
Sector	Health Care
Industries Biotechnology Pharmaceuticals Vaccines

Description

Pulike Biological Engineering, Inc. engages in the research and development, production, and marketing of veterinary biological products and drugs. It offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. The company is headquartered in Luoyang, China.

Key trends

Past 5 years